WVR seeks to add intellectual and financial capital to post-start-up companies that are transitioning from initial market development to an established national/international market presence. Target companies would ideally have revenues of US$10 million to $100 million at the time of our initial investment, although final financing round companies will be considered. These companies would: 1. Have already gained regulatory approvals on their products, and completed development and commercialized their first generation products and services in the U.S. or overseas. Their business would not yet have refined a national or international sales channel, or committed to a commercialization partner... OR.. 2. Have seen commercial success in their initial markets, and are looking to rapidly scale their global supply chain and distribution channels in order to become globally competitive. WVR seeks to invest in companies whose products and services clearly serve a social good by uniquely addressing unmet needs. Medical devices, health IT and healthcare service companies are of prime interest. Other companies with clear value propositions in the industrial or consumer products space might be considered. Of special interest to WVR are companies in ASEAN and Germany/Switzerland/Benelux and Scandanavia. WVR’s first investment is in the Medical Growth Fund of Cleveland, where we Chair its Investment Committee. Its second is in a spinal implant company commercialized in Europe and with PMA clinicals underway in the U.S. WHAT VALUE MIGHT WVR ADD? We bring to all our endeavors a strong set of values and an excellent reputation for integrity and competence earned over 40 years in the healthcare, industrial and consumer products markets. Before retirement in January, we were CEO of Hill-Rom (NYSE: HRC). We are also a principal owner and former CEO of Welch Allyn.